Print FriendlyPrint | Share

CPT Code: 92083  Region: 22

States covered:  Indiana, Iowa, Kansas, Michigan, Missouri, Nebraska

Title:  Visual Field Examination - Extended Intensity

Category
Special Ophthalmological Services

Description
Visual Field Examination, unilateral or bilateral, with interpretation and report; extended examination (eg, Goldmann visual fields with at least 3 isopters plotted and static determination within the central 30i, or quantitative automated threshold perimetry, Octopus Program G-1, 32 or 42, Humphrey visual field analyzer full threshold programs 30-2, 24-2, or 30/60-2)

FEE SCHEDULE



PROCEDURE DESCRIPTION

Visual fields are examined by the use of static or kinetic perimetry.  The procedure is performed separately for each eye, and measures the combined function of the retina, the optic nerve, and the intracranial visual pathway.  It is used clinically to detect or monitor field loss due to disease at any of these locations.  Visual fields may be determined by several methods including a tangent screen, Goldmann perimeter, and computerized automated perimeters.

CLINICAL INDICATIONS

Visual field examinations will be considered medically necessary under the following conditions:

  • Disorder of the eyelids potentially affecting the visual field
  • A documented diagnosis of glaucoma:
    Stabilization or progression of glaucoma can be monitored by a visual field examination, or by such services as scanning computerized ophthalmic diagnostic imaging.  This evaluation must be performed at regular intervals to determine that the prescribed management is adequately controlling progression of disease to the degree possible.  The frequency of such examinations is dependent on clinical judgment as well as the variability of intraocular pressure measurements (i.e., progressive increases despite treatment indicate a worsening condition), the appearance of new hemorrhages and progressive cupping of the optic nerve.
  • A diagnosis of glaucoma is suspected with supporting evidence documented:
    A suspected diagnosis of glaucoma is evidenced by an increase in intraocular pressure over time, intraocular pressures of 22 mm Hg or more, asymmetric intraocular measurements of greater than 2 mm Hg between the two eyes, or has optic nerves suspicious for glaucoma, which may be manifested as asymmetrical cupping, a change in the cup-to-disc ratio over time, disc hemorrhage, or an absent, thinned or notched neural rim. Additional possible indicators of glaucoma suspicion are fallout of the retinal nerve fiber layer, optic atrophy (pallor of the optic nerve), corneal endothelial pigment deposits (Krukenburg’s Spindle), dense pigmentation of the trabecular meshwork as evidenced by gonioscopy, pseudoexfoliation of the lens or dense exfoliative deposits on the trabecular meshwork as evidenced by gonioscopy.
  • A documented disorder of the optic nerve, the neurologic visual pathway, or retina:
    Patients with a previously diagnosed retinal detachment do not need a pretreatment visual field examination. Additionally, patients with an established diagnosed cataract do not need a follow-up visual field unless other presenting symptomatology is documented.  In patients who are about to undergo cataract extraction, who do not have glaucoma and are not glaucoma suspects, a visual field would not be indicated.
  • A recent intracranial hemorrhage, an intracranial mass or a recent measurement of increased intracranial pressure with or without visual symptomatology
  • A recently documented occlusion and/or stenosis of cerebral and precerebral arteries, a recently diagnosed transient cerebral ischemia or giant cell arteritis
  • A history of a cerebral aneurysm, pituitary tumor, occipital tumor or other condition potentially affecting the visual fields
  • A visual field defect demonstrated by gross visual field testing (e.g., confrontation testing)
  • An initial workup for buphthalmos, congenital anomalies of the posterior segment or congenital ptosis
  • A disorder of the orbit, potentially affecting the visual field (e.g. orbital tumor, thyroid disease, etc.)
  • A significant eye injury
  • Unexplained visual loss which may be described as “trouble seeing or vision going in and out”
  • A pale or swollen optic nerve documented by a recent examination
  • New functional limitations which may be due to visual field loss (i.e., reports by family that patient is running into things)
  • Medication treatment (e.g., hydroxychloroquine) which has a high risk of potentially affecting the visual system
  • Initial evaluation for macular degeneration related to central vision loss or has experienced such loss resulting in vision measured at or below 20/70


Limitations

Gross visual field testing (e.g., confrontation testing) is a part of general ophthalmological services and should not be reported separately.

Frequency of examinations for a diagnosis of macular degeneration or an experienced central vision loss (or to evaluate the results of a surgical intervention or for the possible need for surgical intervention) is dictated by stage of disease or degree of risk factors, just as with glaucoma evaluation.

Claims submitted for visual field examinations performed at unusually frequent intervals may be reviewed in order to verify that the services were medically reasonable and necessary.

COVERED DIAGNOSES

ICD-10 Diagnosis Codes



DOCUMENTATION REQUIREMENTS

The medical record documentation must clearly indicate the medical necessity of the visual field testing and the results of the visual field test must be maintained in the patient’s medical record.

Visual field testing is covered for diagnosis and treatment of abnormal signs, symptoms, disease or injury.

The medical record must be made available to Medicare upon request.

When the documentation does not meet the criteria for the service rendered or the documentation does not establish the medical necessity for the services, such services will be denied as not reasonable and necessary under Section 1862(a)(1) of the Social Security Act.

When requesting a written redetermination, (formerly appeal), providers must include all relevant documentation with the request.

There must always be a reason for performing the test since routine exams are considered screening and thus are not covered as medically reasonable and necessary.

CODING GUIDELINES

If the claim contains a separate charge for gross visual fields, it will be denied as an incidental service.

Claims submitted for visual field examinations performed at unusually frequent intervals may be reviewed in order to verify that the services were medically reasonable and necessary.


Claims for visual fields testing services are payable under Medicare Part B in the following places of service:

The global services (technical plus professional) may be billed in the following places of service:

  • Office, nursing facility and independent clinic

The technical component may be billed in the following places of service:

  • Office, nursing facility, independent clinic, federally qualified health center and rural health clinic

The professional component may be billed at the following places of service:

  • Office, off-campus outpatient hospital, inpatient hospital, on-campus outpatient hospital, emergency room, skilled nursing facility, nursing facility, independent clinic and comprehensive outpatient rehabilitation facility

UTILIZATION GUIDELINES

The frequency of examinations for a diagnosis of macular degeneration or an experienced central vision loss (or to evaluate the results of a surgical intervention or for the possible need for surgical intervention) is dictated by stage of disease or degree of risk factors, just as with glaucoma evaluation.

Those examinations found to have been performed at a frequency greater than is necessary for reasonable medical management of the patient’s condition are not covered.

Screening services are not a Medicare benefit.

The use of any particular device for purposes of providing a medically reasonable and necessary service under this LCD is within the discretion of the individual provider, assuming FDA approval and any other applicable regulatory criteria are met. Thus, reference to specific devices is not a subject of this LCD.

CATEGORIES